Mithra Pharmaceuticals Sa Stock Fundamentals
| MITPFDelisted Stock | USD 6.75 0.00 0.00% |
Fundamental analysis of Mithra Pharmaceuticals allows traders to better anticipate movements in Mithra Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
Mithra |
Mithra Pharmaceuticals SA Company Return On Asset Analysis
Mithra Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Mithra Pharmaceuticals Return On Asset | -0.11 |
Most of Mithra Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mithra Pharmaceuticals SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Mithra Pharmaceuticals SA has a Return On Asset of -0.1135. This is 98.7% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is 18.93% lower than that of the firm.
Mithra Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mithra Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Mithra Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mithra Pharmaceuticals competition to find correlations between indicators driving Mithra Pharmaceuticals's intrinsic value. More Info.Mithra Pharmaceuticals SA is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mithra Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Mithra Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mithra Pharmaceuticals' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Mithra Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Mithra Pharmaceuticals by comparing valuation metrics of similar companies.Mithra Pharmaceuticals is currently under evaluation in return on asset category among its peers.
Mithra Fundamentals
| Return On Equity | -1.39 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (3.60) % | |||
| Current Valuation | 425.3 M | |||
| Shares Outstanding | 56.31 M | |||
| Shares Owned By Insiders | 32.32 % | |||
| Shares Owned By Institutions | 15.87 % | |||
| Price To Book | 9.76 X | |||
| Price To Sales | 17.08 X | |||
| Revenue | 22.67 M | |||
| Gross Profit | 6.94 M | |||
| EBITDA | (101.58 M) | |||
| Net Income | (116.88 M) | |||
| Cash And Equivalents | 29.3 M | |||
| Cash Per Share | 0.59 X | |||
| Total Debt | 125.24 M | |||
| Debt To Equity | 9.62 % | |||
| Current Ratio | 0.80 X | |||
| Book Value Per Share | 0.72 X | |||
| Cash Flow From Operations | (74.39 M) | |||
| Earnings Per Share | (2.82) X | |||
| Number Of Employees | 300 | |||
| Beta | 0.49 | |||
| Market Capitalization | 380.13 M | |||
| Total Asset | 421.92 M | |||
| Z Score | 1.8 | |||
| Net Asset | 421.92 M |
About Mithra Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mithra Pharmaceuticals SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mithra Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mithra Pharmaceuticals SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Lige, Belgium. Mithra Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 300 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Mithra Pink Sheet
If you are still planning to invest in Mithra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mithra Pharmaceuticals' history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |